Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan-Reference-Cited by-同舟云学术

Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan

Published:2018-02-26 Issue:1 Volume:34 Page:40-46
ISSN:1868-4300
Container-title:Cardiovascular Intervention and Therapeutics
language:en
Short-container-title:Cardiovasc Interv and Ther

Author:

Aoki Jiro,Kozuma Ken,Awata Masaki,Nanasato Mamoru,Shiode Nobuo,Tanabe Kengo,Yamaguchi Junichi,Kusano Hajime,Nie Hong,Kimura Takeshi,

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/article/10.1007/s12928-018-0515-z/fulltext.html

Reference25 articles.

1. Onuma Y, Miquel-Hebert K, Serruys PW. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. EuroIntervention. 2013;8:1047–51.

2. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013;6:1263–6.

3. Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE Trial (a trial of everolimus-eluting stents and paclitaxel stents for coronary revascularization in daily practice). JACC Cardiovasc Interv. 2015;8:1157–65.

4. Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: 5-year results from SORT OUT IV. J Am Coll Cardiol. 2016;67:751–62.

5. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e002230.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-generation everolimus-eluting intracoronary stents: a comprehensive review of the clinical evidence;Future Cardiology;2024-01-31

2. Prognostic Impacts of CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc-HS Scores on Clinical Outcomes After Elective Drug-Eluting Stent Placement for De Novo Coronary Stenosis;Circulation Reports;2023-04-10

3. Investigation of the small-balloon technique as a method for retrieving dislodged stents;Cardiovascular Intervention and Therapeutics;2023-02-17

4. Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation;Cardiovascular Innovations and Applications;2023

5. Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-;Internal Medicine;2021-01-15